NeuroSearch Phase III trials of NS2330 compound cancelled, no affect.. COPENHAGEN (AFX) - NeuroSearch AS said its partner, Boehringer Ingelheim, has decided not to initiate Phase III clinical studies of the NS2330... [ Click To Open In A New Window ]

	Alzforum: Search Options Home Contact Us Become a Member Your Profile Login Current Papers ARF Recommends Milestone Papers Search All Papers Search Comments Research News Drug News ... [ Click To Open In A New Window ]

	NeuroSearch The drug candidate, NS2330, is a product arising from NeuroSearch's research program within monoamine transporters. [ Click To Open In A New Window ]

	Research: Department of Psychiatry: UI Health Care Psychiatry home Appointments Services and programs Faculty and staff Medical students News Outreach services Patient education information Provider education ... [ Click To Open In A New Window ]

	Neurosearch A/S ... development. NS2330 for Alzheimer's and Parkinson's disease; NS2389 for depression, NS2359 for cocaine addiction, and NS2710 for anxiety. These four compounds are all in clinical Phase ... [ Click To Open In A New Window ]

	Alzforum: Drugs In Clinical Trials - NS2330 ... Name: NS2330 Development Status: investigational FDA Phase: Phase II/IIa/IIb Role in Alzheimer's Disease: The compound enhances the function of the neurotransmitters acetylcholine, ... [ Click To Open In A New Window ]